EDITORIAL article
Front. Pharmacol.
Sec. Experimental Pharmacology and Drug Discovery
Volume 16 - 2025 | doi: 10.3389/fphar.2025.1652445
This article is part of the Research TopicExploring Small Molecule Probes: Advancements and Applications in Pharmacological ResearchView all 6 articles
Editorial: Exploring Small Molecule Probes: Advancements and Applications in Pharmacological Research
Provisionally accepted- Indiana University Indianapolis, Indianapolis, United States
Select one of your emails
You have multiple emails registered with Frontiers:
Notify me on publication
Please enter your email address:
If you already have an account, please login
You don't have a Frontiers account ? You can register here
This Topic brought together researchers with expertise in chemical biology, structural pharmacology, and drug discovery to explore how small molecule probes can be utilized to better understand the proteome, identify disease-relevant targets, and support therapeutic development. The accepted studies in the research topics collectively illustrate the creativity, technical advancement, and translational potential enclosed in small molecule probe research today.One notable contribution, "Utilizing small molecules to probe and harness the proteome by pooled protein tagging with ligandable domains", introduces an elegant strategy to systematically study protein-small molecule interactions. By integrating pooled protein tagging with ligandable domains, this approach offers a scalable way to profile the ligandability of the proteome, which could significantly accelerate probe development pipelines and functional annotation of understudied proteins.In another study, researchers reported the development of a high-throughput acoustic droplet ejection mass spectrometry assay and a solid-supported membrane (SSM)-based electrophysiological assay to study the pharmacological inhibition of SLC1-A3, -A2 and -A1. These assays provide complementary, label-free platforms to investigate the pharmacology of excitatory amino acid transporters, which play crucial roles in neurotransmission and are increasingly being explored as therapeutic targets in neuropsychiatric and neurodegenerative disorders.Using Structure-Based Virtual Screening and Biological Evaluation describes the identification of new FLT3-ITD inhibitors through virtual screening and biological validation. This work not only underscores the utility of in silico techniques in lead discovery but also offers promising scaffolds for further preclinical development.Similarly, the study titled Discovery of novel PARP1/NRP1 dual-targeting inhibitors with strong antitumor potency introduces a multitargeted approach to cancer therapy. By designing dual inhibitors that engage both PARP1 and NRP1, the authors present a strategy that could improve efficacy and overcome resistance mechanisms associated with monotherapy. Such dual-targeting molecules exemplify the expanding capabilities of small molecule probes to modulate complex signaling networks in cancer.The final article, Radiosynthesis and in-vitro identification of a molecular probe 131I-FAPI targeting cancer-associated fibroblasts, highlights the intersection of chemical probe development and diagnostic imaging. Fibroblast activation protein (FAP) has emerged as a relevant target in tumor stroma, and the synthesis of a radiolabeled FAPI probe enables selective detection of cancer-associated fibroblasts. This study offers valuable tools for imaging applications and further supports the idea that molecular probes can bridge therapeutic and diagnostic objectives.Together, these contributions emphasize the versatility and impact of small molecule probes across disciplines-from proteomics and neuropharmacology to oncology and nuclear medicine. Importantly, they demonstrate how methodological advances (e.g., new assay systems, virtual screening platforms, and radiochemical synthesis) are driving the next generation of pharmacological tools.Looking forward, continued progress in this field will require integration of multidisciplinary approaches, including computational chemistry, structural biology, systems pharmacology, and medicinal chemistry. Further attention to probe selectivity, cellular permeability, and in vivo stability will enhance the translational value of these tools. As small molecule probes continue to evolve from research reagents to potential therapeutics, the importance of open, collaborative platforms such as this Research Topic cannot be overstated.We would like to thank all authors who contributed to this collection, the reviewers who provided thoughtful and constructive feedback, and the editorial team for supporting this initiative. We hope this Topic serves as a valuable resource for the community and inspires further innovation in the design and application of small molecule probes in pharmacological research.
Keywords: small molecule probes, Drug Discovery, targeted therapy, High-Throughput Screening, proteome profiling
Received: 23 Jun 2025; Accepted: 24 Jun 2025.
Copyright: © 2025 Yeh. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence: Iju Yeh, Indiana University Indianapolis, Indianapolis, United States
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.